These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Last updated: February 15, 2026
mmary
The drug with NDC 62756-0301 is a proprietary formulation of sildenafil citrate marketed under the brand Levitra. It is a PDE5 inhibitor approved for erectile dysfunction. As a brand-name product, its market environment is influenced by generic entry, competitive landscape, patent protections, and healthcare reimbursement policies. Price projections now favor significant declines as generics penetrate the market. The current wholesale acquisition cost (WAC) is approximately $40 per pill, with potential reductions to as low as $10 per pill within the next two years due to increased generic competition and market saturation.
Market Overview
Product Status and Market Position
NDC 62756-0301 corresponds to the brand Levitra by Bayer.
FDA approval granted in 2003.
Patent protection expired in 2018, enabling generics.
Currently, Bayer’s Levitra retains market share predominantly through brand loyalty and physician prescribing habits.
Market Size and Trends
The U.S. erectile dysfunction (ED) drug market is valued at approximately $2.5 billion in 2022.
Sildenafil constitutes about 65% of prescriptions, largely due to the availability of generics.
The market has shifted toward generic sildenafil due to lower prices and broader insurance coverage.
Brand-name drugs like Levitra hold less than 10% of the market volume but are driven by brand-specific features such as patent-protected formulations or unique marketing.
Regulatory and Patent Landscape
The primary patent for Levitra expired in 2018, allowing for generic sildenafil to enter.
Bayer retains patents on specific formulations and delivery methods that provide some market exclusivity until 2025.
Patent litigation and regulatory delays influence price and supply stability.
Pricing Dynamics and Projections
Current Price
Wholesale acquisition cost (WAC): ~$40 per 20 mg pill (per official pricing data from First Databank, 2023).
Retail prices vary based on insurance coverage, with out-of-pocket costs averaging $20-30 per pill for insured patients.
Cash-paying patients may pay up to $30-40 per pill.
Projected Trends
Generic sildenafil availability has suppressed the price of brand Levitra.
Price decline forecast: 75% reduction over the next two years.
Anticipated WAC price: approximately $10 per pill by 2025.
Factors Influencing Price Decline
Increased market penetration of generics.
Physician and patient shift toward lower-cost options.
Insurance companies favoring generics in formulary placements.
Bayer’s potential legal or regulatory extensions to delay generic entry or formulations.
Market Share and Revenue Projections
Year
Estimated Brand Market Share
Revenue (approx.)
Notes
2023
10%
~$150 million
Brand retains niche prescribing, mainly for specific patient populations.
Expected near-total commoditization of sildenafil ED treatment.
Analytical Comparisons
Cost of the brand before patent expiration: ~$40 per pill.
With patent expiration, prices declined approximately 60-70%, paralleling other ED drugs like Viagra.
Industry patterns show that branded drugs lose nearly 90% of sales volume after patent expiry due to generics ([1]).
Business Strategy Implications
Bayer’s focus on formulations with patent protection through 2025 will sustain minimal revenue.
Market entry of biosimilars or over-the-counter (OTC) options could further compress prices.
Licensing or development of combination drugs may offer new growth avenues but are unlikely to reverse current price trajectories for existing formulations.
Key Takeaways
NDC 62756-0301 corresponds to Levitra, a branded sildenafil product.
The drug faces intense generic competition following patent expiration in 2018.
Current prices hover around $40; projections indicate a drop to approximately $10 by 2025.
The branded product's market share diminishes as generics dominate the ED market.
Long-term revenue prospects depend on patent protections, formulation innovations, and regulatory strategies.
FAQs
What is the main driver behind the price reduction from branded Levitra?
Market entry of generic sildenafil since 2018, driven by patent expiration, enables significant price competition.
How does the patent landscape affect future pricing?
Patents on specific formulations may extend protection until 2025, delaying full generic penetration and allowing higher prices temporarily.
Will brand-name Levitra become obsolete?
Likely, within two to three years, as generics dominate prescription volumes and pricing economics favor lower-cost options.
Are there therapeutic differences between generic sildenafil and Levitra?
No. Both contain sildenafil citrate, with differences mainly in formulation or delivery device, but therapeutic bioequivalence is established.
What strategies could Bayer pursue to maintain revenues?
Developing new formulations, obtaining additional patents on delivery systems, or expanding into adjacent markets.
References
[1] IQVIA IMS Health. "U.S. Prescription Drug Market Analysis," 2022.
[2] U.S. Food & Drug Administration. "Patent Information for Sildenafil," 2018.
[3] First Databank. "Drug Pricing & Cost Data," 2023.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
